← Back to Search

Diagnostic Test

68Ga-PSMA-11 PET Scan for Prostate Cancer

Phase 2

Waitlist Available

Research Sponsored by Clinton Bahler

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the patients underwent a 60minute pet exam. the surgery was generally performed within 1month of the pet scan. the pathology was done 5-10 days after the surgery.

Awards & highlights

Study Summary

This trial will test if PSMA-PET can help predict if cancer has spread outside the prostate and help doctors better treat the cancer while preserving surrounding structures.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 60 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~60 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension

Specificity of PSMA-PET and MRI

Secondary outcome measures

1) Quantify the Frequency of Proper Treatment Changes for Nerve Sparing Directed by PSMA-PET

Trial Design

1Treatment groups

Experimental Treatment

Group I: Men diagnosed with clinically significant prostate cancer who are scheduled for prostatectomyExperimental Treatment1 Intervention

1. Men diagnosed with clinically significant prostate cancer who are scheduled or for prostatectomy will undergo injection of 68Ga-PSMA-11 at the time of their pre-treatment PSMA PET. Followed until 12 mo post surgery

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

68Ga-PSMA-11 PET Scan

2021

Completed Phase 2

~60

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Clinton BahlerLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you elucidate the potential hazards associated with 68Ga-PSMA-11 PET Scanning?

"Assessed on a scale of 1-3, 68Ga-PSMA-11 PET Scan was determined to have safety rating 2 due to being in the Phase 2 trial stage. This means that while there is information supporting its security, no evidence exists yet as it relates to efficacy."

Answered by AI

Is enrollment currently available for this experiment?

"Clinicaltrials.gov reveals that this trial, which was first listed on the 15th of June 2021, is no longer recruiting participants. However, there are over 1,300 other medical studies actively looking for enrolment at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer

Clinton Bahler 2021. "The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04936334.